Why this matters
The legal status of marijuana has been fought over in courtrooms, laboratories, Congress, and statehouses for almost a century. Whether cannabis is Schedule I, Schedule II, decontrolled, or regulated like alcohol determines research access, criminal penalties, banking, patient care, and entire business models. For anyone working in medicine, law, agriculture, or policy, the history of rescheduling efforts explains why the system resists change and what levers remain for reform.
Early regulation: 1900s through 1937
At the turn of the 20th century, cannabis use in the United States was present but not widespread in the ways later feared. The early federal regulatory focus targeted morphine and cocaine. States began to add restrictions on opiates and later on cannabis, often driven by xenophobia and sensationalized press reports. The first major federal intervention specific to cannabis arrived with the Marihuana Tax Act of 1937. That law did not impose a flat ban. It instead created a burdensome tax and registration regime that, in practice, crippled legitimate commerce and pushed much of the market underground.
The Marihuana Tax Act is worth pausing on because it set a pattern: a federal law that nominally targeted a narrow problem but which had broad, hard-to-reverse consequences for growers, patients, and researchers. Hemp, the low-THC form of cannabis used for fiber and seed, suffered in the same sweep even though its properties and uses were distinct.
Postwar consolidation and the Controlled Substances Act
After World War II the federal government continued to tighten controls on psychoactive substances. The big structural change came in 1970 with the Controlled Substances Act. The CSA created the schedules that still organize federal drug policy today, ranking substances by perceived medical value, potential for abuse, and risk of dependence. Marijuana was placed in Schedule I, alongside heroin and LSD, the category for substances that the federal government considered to have no accepted medical use, a high potential for abuse, and no accepted safety for use under medical supervision.
That classification was not inevitable. The impetus for the war on drugs at the federal level had political roots, but it also reflected then-current scientific judgments and social attitudes. After the CSA passed, the Attorney General ordered a scientific review, which produced the Shafer Commission in 1972. The commission, led by Raymond Shafer, recommended decriminalizing simple possession of marijuana for personal use. The Nixon administration largely ignored those recommendations. The Schedule I label remained the legal default for decades.
Rescheduling petitions begin
Once marijuana was cemented into Schedule I, advocates and researchers began the long, formal process of petitioning the federal government to reconsider. Petitioners have used two principal routes. One is administrative: file a rescheduling petition with the Drug Enforcement Administration, which must consult the Department of Health and Human Services and then decide whether to initiate a rulemaking. The other is judicial: sue the DEA or the Department of Justice when petitioners believe the administrative process has been handled unlawfully or unreasonably.
Early administrative petitions date back to the late 1970s and 1980s. Academic researchers, growers seeking to produce study material, and patient advocacy groups pressed for easier research access and lawful medical use. Courts, meanwhile, produced mixed signals. The legal standard for rescheduling is technical: it requires the DEA to weigh scientific and medical evidence, as well as patterns of abuse and dependence. For petitioners, proving that marijuana has an accepted medical use and a different abuse profile than Schedule I drugs has been a high bar.
Key milestones
The 1972 Shafer Commission recommending decriminalization of simple possession. The Controlled Substances Act of 1970 establishing marijuana as Schedule I. The 1996 California initiative that legalized medical cannabis at the state level. The 2018 federal farm bill removing hemp with less than 0.3 percent THC from the CSA. The FDA approval of Epidiolex in 2018 and the DEA scheduling that FDA-approved product in Schedule V.State legalization and federal tension
State-level experiments changed the political and legal landscape. California’s 1996 Proposition 215 legalized medical cannabis and inspired dozens of other states to adopt medical programs. Beginning in 2012 with Colorado and Washington, a wave of adult-use legalization began to take hold. By the early 2020s, a majority of states had some form of medical program and many had legalized recreational use.
Those state actions created a paradox. Under federal law, cannabis remained Schedule I and illegal for any purpose, but millions of people were legally consuming and businesses were operating under state licenses. Federal prosecutors mostly prioritized major trafficking and violent crime, and some federal policies created limited protections for state-legal operators. At the same time the Schedule I classification continued to block mainstream banking, complicated taxation, and made clinical research cumbersome.
The hemp exception
One pragmatic change occurred away from the rescheduling debates. The Agriculture Improvement Act of 2018, commonly called the 2018 farm bill, explicitly removed hemp from the CSA definition of marijuana. Hemp was defined as cannabis and derivatives with no more than 0.3 percent delta-9 THC on a dry weight basis. Removing hemp cleared a regulatory path for fiber, seed, and certain low-THC products, and it confirmed that the federal government could treat different cannabis chemotypes differently. That distinction has been central in later regulatory discussions, because it showed Congress and regulators could, and did, make fine-grained distinctions based on THC content and intended use.
Medical products, FDA, and the Epidiolex precedent
Medical regulation of cannabis has also taken place through the Food and Drug Administration. The FDA approves specific drugs when sponsors submit rigorous clinical data. In 2018 the FDA approved Epidiolex, a cannabidiol product for severe epilepsy, and the DEA placed that approved product into Schedule V. The approval did not reschedule cannabis as a whole, but it created a legal precedent: a component derived from cannabis could be found to have accepted medical use if it met FDA standards. That outcome has often been used by both advocates and skeptics as evidence for different directions. Advocates say if one component can be approved, other cannabinoids might follow. Skeptics and regulators point out that FDA approval requires specific manufacturing controls and clinical trials that most whole-plant products lack.
Notable petitions and agency responses
Across decades multiple petitions targeted DEA rescheduling decisions. One prominent case involved Dr. Lyle Craker, a researcher who petitioned to grow marijuana for research purposes so that clinical scientists would not have to rely on the limited supply from the federal farm program. The DEA repeatedly delayed approvals and courts got involved. The pattern repeated in other petitions: scientific researchers asking for supply, patient groups asking for Schedule II or III classification to enable medical prescriptions, and industry groups pursuing regulatory certainty.
The DEA’s reviews are slow and technical. The agency consults HHS and FDA for scientific and medical analysis. HHS evaluates evidence concerning abuse potential and medical utility; the DEA retains authority to make the final scheduling decision. Often HHS recommendations are one thing and the DEA decision another. That separation of labor produces long delays and gives litigants a pathway to challenge procedures.
In August 2020 HHS issued a recommendation that surprised some observers, suggesting a move away from Schedule I and toward a lower schedule. The HHS analysis acknowledged medical uses and suggested rescheduling to Schedule III might be appropriate. That recommendation came amid a more permissive regulatory environment in many states and new clinical studies. The DEA response to that recommendation has been procedural and measured, reflecting the agency’s statutory responsibilities and the political complexity of altering a multi-decade framework.
Federal executive action and the Biden administration review
Presidential priorities shape rescheduling in ways statutes do not. Executive orders, pardons, and agency memos affect enforcement and the pace of scientific review. Some presidents issued statements directing more lenient enforcement for small possession, while others prioritized interdiction.
The Biden administration took several visible steps that signaled a willingness to reassess federal marijuana policy. One executive action was a limited presidential pardon for federal simple possession offenses, paired with a request that the attorney general and HHS initiate a review of marijuana’s classification under the CSA. That directive launched administrative reviews, but it did not itself change the schedules. Administrative rulemaking remains the vehicle for formal rescheduling.
Why rescheduling matters practically
Rescheduling or descheduling cannabis has consequences that ripple through law and daily practice. If marijuana remained in Schedule I, researchers face higher security and licensing burdens, pharmaceutical companies face obstacles to standardizing products, and criminal statutes continue to carry sometimes severe penalties. If marijuana moved to Schedule II or III, prescriptions and pharmaceutical pathways might become viable for certain products, banks might find clearer compliance paths, and sentences for possession could drop. If Congress or agencies descheduled marijuana entirely, it would free states to regulate commerce without federal criminal overlay, but it would also raise questions about interstate commerce, taxation, and standards for product safety.
There are trade-offs. Moving marijuana to Schedule III, as HHS has at times suggested, could facilitate medical research and loosen some criminal penalties, but it would still impose significant regulatory controls. Physicians would have to prescribe controlled substances within the existing framework. Descheduling entirely would transfer authority primarily to states and require Congress to resolve tax and commerce questions. That outcome could spur rapid market growth but also raise public health concerns about youth access, impaired driving, and quality control.
Courts and litigation as policy engines
When administrative processes stall, litigants turn to courts. Several lawsuits have challenged the DEA for dismissing petitions or delaying determination. Courts examine whether the agency followed required procedures, gave adequate reasons, and considered the best available science. Litigation has sometimes nudged the DEA to act more promptly, but courts rarely substitute their own scientific judgment for agency expertise. As a result, litigation can force the agency to explain decisions in more detail without necessarily changing the outcome.
States created another pressure valve. When dozens of states adopt medical or adult-use systems, the contrast between federal law and local practice becomes harder to justify. Congress faces pressure to reconcile inconsistent federal and state policies, but politics and congressional gridlock have slowed that route. Instead, incremental shifts from administrative agencies, executive discretion, and targeted federal laws like the farm bill have produced a patchwork rather than a single coherent federal policy.
Research constraints and the supply problem
A persistent, practical barrier to rescheduling is research. High-quality clinical trials require standardized, quality-controlled products and predictable supply. Under Schedule I researchers must comply with strict storage, recordkeeping, and security requirements. The federal system for producing research marijuana has often been criticized as limited and not representative of the market in states where cannabis is legal.
The supply constraint is both a scientific and legal argument for rescheduling. Advocates say that more realistic research material would permit better evaluation of therapeutic effects and risks. Regulators worry that loosening controls without adequate safeguards could increase misuse. That tension explains why HHS scientific reviews focus heavily on the availability of data and why the DEA weighs both public health and law enforcement factors in its decisions.
Politics and public opinion
Public opinion has shifted dramatically over recent decades. Gallup and other polls show growing majority support for legalization, an important political fact because elected officials respond to their constituents. That shift is reflected in state laws and in some congressional proposals. Yet national politics remain divided. Criminal justice reformers, medical advocates, law enforcement, and public health experts disagree about the best path forward, producing a patchwork of proposals that range from full descheduling to narrowly targeted medical rescheduling or expanded research access.
What remains unresolved
Several practical questions remain central to any rescheduling debate. One concerns the unit of regulation: should the law treat cannabis as a single monolithic substance, or should it differentiate by cannabinoid profile, dosage, or route of administration? The distinction between hemp and marijuana already recognizes one such divide. Another question is enforcement priority: how aggressively will federal prosecutors pursue violations in state-legal contexts? A third is market regulation: who will oversee labeling, potency limits, testing, and advertising if federal criminal constraints are relaxed?
For practitioners and business people, watching agency rulemakings and HHS scientific reports is the most immediate concern. For patients and clinicians, the availability of standardized, FDA-regulated medicines matters most. For advocates and civil rights lawyers, the reduction of collateral consequences from federal conviction — housing, employment, and immigration effects — remains urgent.
Practical takeaways from the history
First, administrative law matters. Filing a petition, gathering clinical data, and building legal arguments in administrative terms often matters more than political speech. Second, change is incremental. Major reclassifications have been the result Ministry of Cannabis of a combination of legal pressure, scientific evidence, and shifting political winds rather than a single decisive act. Third, state experiments have mattered. The proliferation of state medical and adult-use programs changed the facts on the ground and created pressure for federal reconsideration. Fourth, product-specific approvals show a practical path for medical acceptance, but they do not resolve the broader legal contradictions between state and federal regimes.
A note on language and categories
Words matter in these debates. Cannabis and marijuana are often used interchangeably, but hemp denotes low-THC varieties with agricultural uses. The policy choices differ depending on which term you use. Precision helps: when discussing research, specify the cannabinoid profile and the product form. When discussing regulation, be explicit about whether you mean rescheduling under the CSA, decriminalization, or state legalization.
What to watch next
Future milestones to watch include any formal DEA rulemaking that follows HHS recommendations, congressional bills that propose federal frameworks, court decisions that clarify administrative obligations, and FDA approvals for additional cannabinoid-derived medicines. Monitoring how states update their rules for interstate commerce, labeling, and testing will also reveal the practical implications of any federal changes.
An ecosystem locked into a nearly century-old decision now confronts knowledge produced by modern science, an industry built under state law, and a public that has shifted its views. The legal history of rescheduling efforts shows an uneven, technical, and often slow-moving process. But it also shows that sustained petitions, litigation, public pressure, and incremental legal victories can reshape a framework that once seemed immovable. The next substantive change may come from federal agencies, Congress, or the courts, but whatever path it follows will reflect lessons learned from decades of fits and starts, narrow approvals, and the power of state-level experimentation.